文献速递肿瘤 PET/CT

18F-胆碱PET/mpMRI提升前列腺癌风险分层

18F-Choline PET/mpMRI for Detection of Clinically Significant Prostate Cancer: Part 1. Improved Risk Stratification for MRI-Guided Transrectal Prostate Biopsies.
PubMed 文献 · J Nucl Med · 2019-08-16

一项前瞻性单臂临床试验纳入56例可评估受试者、90个Likert评分3-5的mpMRI靶病灶,评估18F-胆碱PET/mpMRI能否提高mpMRI对Gleason≥3+4前列腺癌的特异性。结果显示,联合模型将病灶水平准确率显著提升至88.9%(Likert)和91.1%(PI-RADS),主要效应为改善中危mpMRI病灶的风险分层。

要点

  • 18F-胆碱PET/mpMRI可提高Gleason≥3+4前列腺癌的检出准确率。
  • 联合模型主要改善中危mpMRI病灶(Likert 4或PI-RADS 3-4)的风险分层。
  • 以18F-胆碱靶本比>1.58为阳性标准,病灶水平准确率显著提升。

核心结论

  • 与单独mpMRI相比,18F-胆碱PET/mpMRI改善了Gleason≥3+4前列腺癌的识别,主要效应为改善中危mpMRI病灶的风险分层。

研究设计与样本

  • 前瞻性单臂临床试验,纳入56例可评估受试者、90个Likert评分3-5的mpMRI靶病灶。
  • 在靶向和系统穿刺活检前行mpMRI和18F-胆碱PET/CT,以靶本比>1.58为18F-胆碱阳性标准。
  • 采用混合效应逻辑回归比较mpMRI与18F-胆碱PET/mpMRI检测Gleason≥3+4癌症的性能。

主要发现

  • 单独mpMRI的病灶水平准确率:Likert 4-5为67.8%(AUC 0.73),PI-RADS 3-5为70.0%(AUC 0.76)。
  • 联合模型(所有高危病灶加中低危病灶伴靶本比>1.58)病灶水平准确率:Likert为88.9%(AUC 0.90,P<0.001),PI-RADS为91.1%(AUC 0.92,P<0.001)。
  • 联合模型患者水平准确率:Likert为92.9%(AUC 0.93,P<0.001),PI-RADS为91.1%(AUC 0.91,P=0.009)。

关键数值与推荐

  • 18F-胆碱阳性标准:靶本比>1.58。
  • 联合模型纳入所有高危病灶(Likert 5或PI-RADS 5)加中低危病灶(Likert 4或PI-RADS 3-4)伴靶本比>1.58。

临床怎么用

  • 对于mpMRI中危病灶(Likert 4或PI-RADS 3-4),可结合18F-胆碱PET靶本比>1.58改善风险分层。
  • 18F-胆碱PET/mpMRI联合模型有助于提高Gleason≥3+4前列腺癌的检出准确率。

局限性

  • 前瞻性单臂设计,样本量有限(56例可评估受试者、90个病灶)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A prospective single-arm clinical trial was conducted to determine whether 18F-choline PET/mpMRI can improve the specificity of multiparametric MRI (mpMRI) of the prostate for Gleason ≥ 3+4 prostate cancer. Methods: Before targeted and systematic prostate biopsy, mpMRI and 18F-choline PET/CT were performed on 56 evaluable subjects with 90 Likert score 3-5 mpMRI target lesions, using a 18F-choline target-to-background ratio of greater than 1.58 to indicate a positive 18F-choline result. Prostate biopsies were performed after registration of real-time transrectal ultrasound with T2-weighted MRI. A mixed-effects logistic regression was applied to measure the performance of mpMRI (based on prospective Likert and retrospective Prostate Imaging Reporting and Data System, version 2 [PI-RADS], scores) compared with 18F-choline PET/mpMRI to detect Gleason ≥ 3+4 cancer. Results: The per-lesion accuracy of systematic plus targeted biopsy for mpMRI alone was 67.8% (area under receiver-operating-characteristic curve [AUC], 0.73) for Likert 4-5 and 70.0% (AUC, 0.76) for PI-RADS 3-5. Several PET/MRI models incorporating 18F-choline with mpMRI data were investigated. The most promising model selected all high-risk disease on mpMRI (Likert 5 or PI-RADS 5) plus low- and intermediate-risk disease (Likert 4 or PI-RADS 3-4), with an elevated 18F-choline target-to-background ratio greater than 1.58 as positive for significant cancer. Using this approach, the accuracy on a per-lesion basis significantly improved to 88.9% for Likert (AUC, 0.90; P < 0.001) and 91.1% for PI-RADS (AUC, 0.92; P < 0.001). On a per-patient basis, the accuracy improved to 92.9% for Likert (AUC, 0.93; P < 0.001) and to 91.1% for PI-RADS (AUC, 0.91; P = 0.009). Conclusion:18F-choline PET/mpMRI improved the identification of Gleason ≥ 3+4 prostate cancer compared with mpMRI, with the principal effect being improved risk stratification of intermediate-risk mpMRI lesions.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Davenport MS, Montgomery JS, Kunju LP, et al. 18F-Choline PET/mpMRI for Detection of Clinically Significant Prostate Cancer: Part 1. Improved Risk Stratification for MRI-Guided Transrectal Prostate Biopsies. J Nucl Med. 2019. PMID: 31420496. doi:10.2967/jnumed.119.225789

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。